Biotech | May 10, 2022
Bora Pharmaceuticals acquires Eden Biologics CDMO assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
New product line to address the challenge of restrictions on use of plastic straws
Both companies have been selected for stand-by production by German government
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The new facility is scheduled to start operation in the first half of 2024
Supply increase to help meet growing global demand
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
Subscribe To Our Newsletter & Stay Updated
